Corcept Therapeutics Incorporated
CORT
Pozycja w akcjach
#1818
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Cena akcji
$109.25
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$11.81B
Zmiana (1 dzień)
-3.64%
Zmiana (1 rok)
38.83%
Kraj
US
Handel Corcept Therapeutics Incorporated (CORT)
Kategoria
Healthcare
EPS dla Corcept Therapeutics Incorporated (CORT)
EPS na dzień June 2026 TTM: $0.52
Według najnowszych raportów finansowych i ceny akcji firmy Corcept Therapeutics Incorporated, obecny EPS (TTM) wynosi $0.52. Na koniec roku 2023 firma miała EPS w wysokości $1.02, wzrost w porównaniu do do EPS z roku 2022, który wynosił $0.95.
Historia EPS dla Corcept Therapeutics Incorporated od 2001 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $0.52 | -61.48% |
| 2024 | $1.35 | 32.35% |
| 2023 | $1.02 | 7.37% |
| 2022 | $0.95 | -2.06% |
| 2021 | $0.97 | 5.43% |
| 2020 | $0.92 | 12.20% |
| 2019 | $0.82 | 36.67% |
| 2018 | $0.60 | -47.37% |
| 2017 | $1.14 | 1,528.57% |
| 2016 | $0.07 | -216.67% |
| 2015 | $-0.06 | -80.65% |
| 2014 | $-0.31 | -32.61% |
| 2013 | $-0.46 | 12.20% |
| 2012 | $-0.41 | 5.13% |
| 2011 | $-0.39 | 2.63% |
| 2010 | $-0.38 | 0.00% |
| 2009 | $-0.38 | -11.63% |
| 2008 | $-0.43 | 26.47% |
| 2007 | $-0.34 | -68.81% |
| 2006 | $-1.09 | 22.47% |
| 2005 | $-0.89 | 5.95% |
| 2004 | $-0.84 | -25.66% |
| 2003 | $-1.13 | -58.91% |
| 2002 | $-2.75 | 97.84% |
| 2001 | $-1.39 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $2.41 | 363.46% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -96.38% |
HK
|
